International journal of thyroidology

Korean Thyroid Association (대한갑상선학회)
권호 표지
DOI QR코드

DOI QR Code

Skin-Related Toxicity of Tyrosine Kinase Inhibitor in Thyroid Cancer

갑상선암에서 표적치료항암제의 피부 관련 부작용

  • Lim, Dong-Jun (Division of Endocrinology and Metabolism, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea)
  • 임동준 (가톨릭대학교 의과대학 서울성모병원 내분비내과)
  • Received : 2018.10.25
  • Accepted : 2018.11.28
  • Published : 2018.11.30
⟨ Previous Next ⟩

Abstract

Skin-related toxicity is one of the most important adverse events from multi-target tyrosine kinase inhibitor (MTKI) to treat radioiodine refractory thyroid cancer. As hand foot skin reaction can limit quality of life and therapeutic effectiveness, it is essential to cope with a variety of severity of skin-related toxicity induced by MTKI. Herein, we will discuss two representative cases of skin-related toxicities which were managed by discontinuation/reduction of therapeutic doses of MTKI and were treated by proper medication in thyroid cancer patients with distant metastasis.

Keywords

References

  1. Brose MS, Nutting CM, Jarzab B, Elisei R, Siena S, Bastholt L, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet 2014;384(9940):319-28. https://doi.org/10.1016/S0140-6736(14)60421-9
  2. Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, et al. Lenvatinib versus placebo in radioiodinerefractory thyroid cancer. N Engl J Med 2015;372(7):621-30. https://doi.org/10.1056/NEJMoa1406470
  3. Chanprapaph K, Rutnin S, Vachiramon V. Multikinase inhibitor-induced hand-foot skin reaction: A review of clinical presentation, pathogenesis, and management. Am J Clin Dermatol 2016;17(4):387-402. https://doi.org/10.1007/s40257-016-0197-1
  4. Resteghini C, Cavalieri S, Galbiati D, Granata R, Alfieri S, Bergamini C, et al. Management of tyrosine kinase inhibitors (TKI) side effects in differentiated and medullary thyroid cancer patients. Best Pract Res Clin Endocrinol Metab 2017;31(3):349-61. https://doi.org/10.1016/j.beem.2017.04.012
  5. Jean GW, Mani RM, Jaffry A, Khan SA. Toxic effects of sorafenib in patients with differentiated thyroid carcinoma compared with other cancers. JAMA Oncol 2016;2(4):529-34. https://doi.org/10.1001/jamaoncol.2015.5927
  6. Erber R, Thurnher A, Katsen AD, Groth G, Kerger H, Hammes HP, et al. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J 2004;18(2):338-40. https://doi.org/10.1096/fj.03-0271fje
  7. Jain L, Gardner ER, Figg WD, Chernick MS, Kong HH. Lack of association between excretion of sorafenib in sweat and hand-foot skin reaction. Pharmacotherapy 2010;30(1):52-6. https://doi.org/10.1592/phco.30.1.52
  8. Brose MS, Cabanillas ME, Cohen EE, Wirth LJ, Riehl T, Yue H, et al. Vemurafenib in patients with BRAF(V600E)- positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial. Lancet Oncol 2016;17(9):1272-82. https://doi.org/10.1016/S1470-2045(16)30166-8
  9. Brose MS, Frenette CT, Keefe SM, Stein SM. Management of sorafenib-related adverse events: a clinician's perspective. Semin Oncol 2014;41 Suppl 2:S1-S16.